Oncolytics Biotech enters ATM agreement for up to $75M common stock offering

ONCOLYTICS BIOTECH INC

Agreement with Jefferies LLC allows sale of up to $75M in common stock at market prices.
Proceeds to fund clinical development of pelareorep, R&D, operating costs, and general corporate purposes.
Jefferies will receive a commission of 3.0% of gross proceeds; company also reimburses certain expenses.
Shares sold under shelf registration effective April 3, 2026; prospectus supplement filed April 6, 2026.
Company is not obligated to sell any shares; either party may terminate on ten trading days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.